Skip to main content
SpringerLink
Log in
Book cover

Immunotherapy for Gastrointestinal Cancer pp 23–46Cite as

Cell Based Therapy: Modified Cancer Cells

  • Chapter
  • First Online:

  • 766 Accesses

Abstract

Colorectal cancer remains a major cause of morbidity and mortality throughout the world, with an incidence that is on the rise. Considering the limitations of surgery and adjuvant chemo and/or radiation therapy in treating CRC patients, a greater emphasis has been placed on developing alternative treatment approaches including immunotherapy. This chapter will focus on autologous cell based immunotherapy including adoptive T cell transfer, dendritic cell based vaccines and autologous tumour cell derived vaccines targeting CRC. Also the possibilities of combining immunotherapy with conventional treatment strategies will be briefly explored.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Zumwalt TJ, Goel A. Immunotherapy of metastatic colorectal cancer: prevailing challenges and new perspectives. Curr Colorectal Cancer Rep. 2015;11(3):125–40.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Zhen Y-H, Liu X-H, Yang Y, Li B, Tang J-L, Zeng Q-X, et al. Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer. Cancer Immunol Immunother. 2015;64(9):1083–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Koido S, Ohkusa T, Homma S, Namiki Y, Takakura K, Saito K, et al. Immunotherapy for colorectal cancer. World J Gastroenterol. 2013;19(46):8531–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Karlsson M, Marits P, Dahl K, Dagöö T, Enerbäck S, Thörn M, et al. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol. 2010;17(7):1747–57.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Amedei A, Niccolai E, D’Elios MM. T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology. Clin Dev Immunol. 2011;2011:320571.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Manik Amin ACL, Lockhart AC. The potential role of immunotherapy to treat colorectal cancer. Expert Opin Investig Drugs. Informa UK, Ltd; 2015 (3):329–44.

    Google Scholar 

  7. Pernot S, Terme M, Voron T, Colussi O, Marcheteau E, Tartour E, et al. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol. 2014;20(14):3738–50.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Deschoolmeester V, Smits E, Peeters M, Vermorken JB. Status of active specific immunotherapy for stage II, stage III, and resected stage IV colon cancer – springer. Curr Colorectal Cancer Rep. 2013;9:380–90.

    Article  Google Scholar 

  9. Boghossian S, Robinson S, Von Delwig A, Manas D, White S. Immunotherapy for treating metastatic colorectal cancer. Surg Oncol. 2012;21(2):67–77.

    Article  PubMed  Google Scholar 

  10. Deschoolmeester V, Baay M, Lardon F, Pauwels P, Peeters M. Immune cells in colorectal cancer: prognostic relevance and role of MSI. Cancer Microenviron. 2011;4(3):377–92.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Loose D, Van de Wiele C. The immune system and cancer. Cancer Biother Radiopharm. 2009;24(3):369–76.

    Article  CAS  PubMed  Google Scholar 

  12. Kalinski P. Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs. 2009;10(6):526–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Xiang B, Snook AE, Magee MS, Waldman SA. Colorectal cancer immunotherapy. Discov Med. 2013;15(84):301–8.

    PubMed  PubMed Central  Google Scholar 

  14. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676–80.

    Article  CAS  PubMed  Google Scholar 

  15. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Aglietta M, Barkholt L, Schianca FC, Caravelli D, Omazic B, Minotto C, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. Biol Blood Marrow Transplant. 2009;15(3):326–35.

    Article  CAS  PubMed  Google Scholar 

  17. Satoh K, Kan N, Okino T, Mise K, Yamasaki S, Harada T, et al. The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from gastric or colorectal cancers. Biotherapy. 1993;6(1):41–9.

    Article  CAS  PubMed  Google Scholar 

  18. Kono K, Ichihara F, Iizuka H, Sekikawa T, Matsumoto Y. Expression of signal transducing T-cell receptor zeta molecules after adoptive immunotherapy in patients with gastric and colon cancer. Int J Cancer. 1998;78(3):301–5.

    Article  CAS  PubMed  Google Scholar 

  19. Gardini A, Ercolani G, Riccobon A, Ravaioli M, Ridolfi L, Flamini E, et al. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J Surg Oncol. 2004;87(1):46–52.

    Article  PubMed  Google Scholar 

  20. Ishikawa T, Kokura S, Sakamoto N, Matsumoto T, Funaki J, Adachi S, et al. Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells. Exp Ther Med. 2011;2(4):737–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan D-AN, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620–6.

    Article  CAS  PubMed  Google Scholar 

  22. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Carluccio S, Delbue S, Signorini L, Setola E, Bagliani A, Valle Della A, et al. Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer. J Cell Physiol. 2015;230(7):1457–65.

    Article  CAS  PubMed  Google Scholar 

  24. Yanagawa E, Uchida A, Micksche M. Natural cytotoxicity of lymphocytes from lymph nodes draining breast carcinoma and its augmentation by interferon and OK432. Cancer Immunol Immunother. 1984;17(1):1–6.

    Article  CAS  PubMed  Google Scholar 

  25. Marits P, Karlsson M, Dahl K, Larsson P, Wanders A, Thörn M, et al. Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer. 2006;94(10):1478–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Chou J, Voong LN, Mortales CL, Towlerton AMH, Pollack SM, Chen X, et al. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother. 2012;35(2):131–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1–30.

    Article  CAS  PubMed  Google Scholar 

  28. Liu F, Hu X, Zimmerman M, Waller JL, Wu P, Hayes-Jordan A, et al. TNFα cooperates with IFN-γ to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis. PLoS One. 2011;6(1):e16241.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Burgdorf SK. Dendritic cell vaccination of patients with metastatic colorectal cancer. Dan Med Bull. 2010;57(9):B4171.

    PubMed  Google Scholar 

  31. Weihrauch MR, Ansén S, Jurkiewicz E, Geisen C, Xia Z, Anderson KS, et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res. 2005;11(16):5993–6001.

    Article  CAS  PubMed  Google Scholar 

  32. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res. 1999;5(6):1331–8.

    CAS  PubMed  Google Scholar 

  33. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 2001;98(15):8809–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology. 2001;48(38):347–51.

    CAS  PubMed  Google Scholar 

  35. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res. 2001;7(8):2277–84.

    CAS  PubMed  Google Scholar 

  36. Toungouz M, Libin M, Bulté F, Faid L, Lehmann F, Duriau D, et al. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol. 2001;69(6):937–43.

    CAS  PubMed  Google Scholar 

  37. Itoh T, Ueda Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N, et al. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother. 2002;51(2):99–106.

    Article  CAS  PubMed  Google Scholar 

  38. Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. 2003;21(3):341–9.

    Article  CAS  PubMed  Google Scholar 

  39. Liu K-J, Wang C-C, Chen L-T, Cheng A-L, Lin D-T, Wu Y-C, et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res. 2004;10(8):2645–51.

    Article  CAS  PubMed  Google Scholar 

  40. Matsuda K, Tsunoda T, Tanaka H, Umano Y, Tanimura H, Nukaya I, et al. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother. 2004;53(7):609–16.

    Article  CAS  PubMed  Google Scholar 

  41. Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y, et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol. 2004;24(4):909–17.

    CAS  PubMed  Google Scholar 

  42. Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res. 2005;11(8):3017–24.

    Article  CAS  PubMed  Google Scholar 

  43. Babatz J, Röllig C, Löbel B, Gunnar F, Haack M, Günther H, et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother. 2006;55(3):268–76.

    Article  CAS  PubMed  Google Scholar 

  44. Burgdorf SK, Fischer A, Claesson MH, Kirkin AF, Dzhandzhugazyan KN, Rosenberg J. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study. J Exp Clin Cancer Res. 2006;25(2):201–6.

    CAS  PubMed  Google Scholar 

  45. Lesterhuis WJ, de Vries IJM, Schuurhuis DH, Boullart ACI, Jacobs JFM, de Boer AJ, et al. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol. 2006;17(6):974–80.

    Article  CAS  PubMed  Google Scholar 

  46. Lou E, Marshall J, Aklilu M, Cole D, Chang D, Morse M. A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. Clin Colorectal Cancer. 2006;5(5):368–71.

    Article  PubMed  Google Scholar 

  47. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother. 2006;55(9):1122–31.

    Article  PubMed  Google Scholar 

  48. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007;30(7):762–72.

    Article  CAS  PubMed  Google Scholar 

  49. Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother. 2007;56(12):2003–16.

    Article  PubMed  Google Scholar 

  50. Burgdorf SK, Fischer A, Myschetzky PS, Munksgaard SB, Zocca M-B, Claesson MH, et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep. 2008;20(6):1305–11.

    PubMed  Google Scholar 

  51. Tanaka F, Haraguchi N, Isikawa K, Inoue H, Mori M. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. Oncol Rep. 2008;20(5):1111–6.

    PubMed  Google Scholar 

  52. Burgdorf SK, Claesson MH, Nielsen HJ, Rosenberg J. Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination. Acta Oncol. 2009;48(8):1157–64.

    Article  CAS  PubMed  Google Scholar 

  53. Barth RJ, Fisher DA, Wallace PK, Channon JY, Noelle RJ, Gui J, et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res. 2010;16(22):5548–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Lesterhuis WJ, de Vries IJM, Aarntzen EA, de Boer A, Scharenborg NM, van de Rakt M, et al. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer. 2010;103(9):1415–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Lesterhuis WJ, De Vries IJM, Schreibelt G, Schuurhuis DH, Aarntzen EH, De Boer A, et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res. 2010;30(12):5091–7.

    PubMed  Google Scholar 

  56. Sakakibara M, Kanto T, Hayakawa M, Kuroda S, Miyatake H, Itose I, et al. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol Immunother. 2011;60(11):1565–75.

    Article  CAS  PubMed  Google Scholar 

  57. Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 2013;7.

    Google Scholar 

  58. Park M-Y, Kim C-H, Sohn H-J, Oh S-T, Kim S-G, Kim T-G. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity. Vaccine. 2007;25(42):7322–30.

    Article  CAS  PubMed  Google Scholar 

  59. Lou Y, Wang G, Lizée G, Kim GJ, Finkelstein SE, Feng C, et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 2004;64(18):6783–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Katano M, Morisaki T, Koga K, Nakamura M, Onishi H, Matsumoto K, et al. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res. 2005;25(6A):3771–6.

    PubMed  Google Scholar 

  61. Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ, van der Burg SH. Colorectal cancer vaccines in clinical trials. Expert Rev Vaccines. 2011;10(6):899–921.

    Article  CAS  PubMed  Google Scholar 

  62. Hoover HC, Surdyke M, Dangel RB, Peters LC, Hanna MG. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine. Cancer Res. 1984;44(4):1671–6.

    PubMed  Google Scholar 

  63. Hoover HC, Surdyke MG, Dangel RB, Peters LC, Hanna MG. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer. 1985;55(6):1236–43.

    Article  PubMed  Google Scholar 

  64. Hoover HC, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993;11(3):390–9.

    PubMed  Google Scholar 

  65. Harris JE, Ryan L, Hoover HC, Stuart RK, Oken MM, Benson AB, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000;18(1):148–57.

    CAS  PubMed  Google Scholar 

  66. Liang W, Wang H, Sun T-M, Yao W-Q, Chen L-L, Jin Y, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol. 2003;9(3):495–8.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999;353(9150):345–50.

    Article  CAS  PubMed  Google Scholar 

  68. Uyl-de Groot CA, Vermorken BJ, Hanna MG, Verboom P, Groot MT, Bonsel GJ, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005;23(17–18):2379–87.

    Article  CAS  PubMed  Google Scholar 

  69. Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res. 1996;2(1):21–8.

    CAS  PubMed  Google Scholar 

  70. Schulze T, Kemmner W, Weitz J, Wernecke K-D, Schirrmacher V, Schlag PM. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother. 2009;58(1):61–9.

    Article  CAS  PubMed  Google Scholar 

  71. de Weger VA, Turksma AW, Voorham QJM, Euler Z, Bril H, van den Eertwegh AJ, et al. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer. Clin Cancer Res. 2012;18(3):882–9.

    Article  PubMed  Google Scholar 

  72. Baars A, Claessen AME, Wagstaff J, Giaccone G, Scheper RJ, Meijer S, et al. A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer. 2002;86(8):1230–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Oncological Research (CORE) Antwerp, University of Antwerp, Antwerp, Belgium

    Vanessa Deschoolmeester & Jan B. Vermorken

  2. Department of Pathology, Antwerp University Hospital, Edegem, Belgium

    Vanessa Deschoolmeester & Patrick Pauwels

  3. Nuffield Division of Clinical and Laboratory Sciences, University of Oxford, Oxford, UK

    David Kerr

  4. Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium

    Jan B. Vermorken

Authors
  1. Vanessa Deschoolmeester
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Kerr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick Pauwels
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan B. Vermorken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vanessa Deschoolmeester .

Editor information

Editors and Affiliations

  1. Nuffield Division of Clinical and Laboratory Sciences, University of Oxford, Oxford, United Kingdom

    David Kerr

  2. John Radcliffe Hospital, Oxford University Hospitals NHS Trust John Radcliffe Hospital, Oxfordshire, United Kingdom

    Rebecca Johnson

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Deschoolmeester, V., Kerr, D., Pauwels, P., Vermorken, J.B. (2017). Cell Based Therapy: Modified Cancer Cells. In: Kerr, D., Johnson, R. (eds) Immunotherapy for Gastrointestinal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-43063-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43063-8_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43061-4

  • Online ISBN: 978-3-319-43063-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation